Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Environ Health Perspect. 2004 Apr; 112(5): 599–603.
PMCID: PMC1241927
PMID: 15064167

Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: a dose-response study.

Abstract

The present study was designed to establish the form of the dose-response relationship for dietary sodium arsenite as a co-carcinogen with ultraviolet radiation (UVR) in a mouse skin model. Hairless mice (strain Skh1) were fed sodium arsenite continuously in drinking water starting at 21 days of age at concentrations of 0.0, 1.25, 2.5, 5.0, and 10 mg/L. At 42 days of age, solar spectrum UVR exposures were applied three times weekly to the dorsal skin at 1.0 kJ/m2 per exposure until the experiment ended at 182 days. Untreated mice and mice fed only arsenite developed no tumors. In the remaining groups a total of 322 locally invasive squamous carcinomas occurred. The carcinoma yield in mice exposed only to UVR was 2.4 +/- 0.5 cancers/mouse at 182 days. Dietary arsenite markedly enhanced the UVR-induced cancer yield in a pattern consistent with linearity up to a peak of 11.1 +/- 1.0 cancers/mouse at 5.0 mg/L arsenite, representing a peak enhancement ratio of 4.63 +/- 1.05. A decline occurred to 6.8 +/- 0.8 cancers/mouse at 10.0 mg/L arsenite. New cancer rates exhibited a consistent-with-linear dependence on time beginning after initial cancer-free intervals ranging between 88 and 95 days. Epidermal hyperplasia was elevated by arsenite alone and UVR alone and was greater than additive for the combined exposures as were growth rates of the cancers. These results demonstrate the usefulness of a new animal model for studying the carcinogenic action of dietary arsenite on skin exposed to UVR and should contribute to understanding how to make use of animal data for assessment of human cancer risks in tissues exposed to mixtures of carcinogens and cancer-enhancing agents.

Full Text

The Full Text of this article is available as a PDF (3.2M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R, Menzer R, Rossman T, Thompson C, et al. Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect. 1999 Jul;107(7):593–597. [PMC free article] [PubMed] [Google Scholar]
  • Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, Dudek EJ. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65–75. [PubMed] [Google Scholar]
  • Bau Da-Tian, Wang Tsu-Shing, Chung Chiao-Hui, Wang Alexander S S, Wang Alexander S S, Jan Kun-Yan. Oxidative DNA adducts and DNA-protein cross-links are the major DNA lesions induced by arsenite. Environ Health Perspect. 2002 Oct;110 (Suppl 5):753–756. [PMC free article] [PubMed] [Google Scholar]
  • Brown KG, Boyle KE, Chen CW, Gibb HJ. A dose-response analysis of skin cancer from inorganic arsenic in drinking water. Risk Anal. 1989 Dec;9(4):519–528. [PubMed] [Google Scholar]
  • Brown KG, Guo HR, Kuo TL, Greene HL. Skin cancer and inorganic arsenic: uncertainty-status of risk. Risk Anal. 1997 Feb;17(1):37–42. [PubMed] [Google Scholar]
  • Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog. 2001 Feb;30(2):79–87. [PubMed] [Google Scholar]
  • Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol. 2001 Mar 1;153(5):411–418. [PubMed] [Google Scholar]
  • Corsini E, Asti L, Viviani B, Marinovich M, Galli CL. Sodium arsenate induces overproduction of interleukin-1alpha in murine keratinocytes: role of mitochondria. J Invest Dermatol. 1999 Nov;113(5):760–765. [PubMed] [Google Scholar]
  • Germolec DR, Spalding J, Boorman GA, Wilmer JL, Yoshida T, Simeonova PP, Bruccoleri A, Kayama F, Gaido K, Tennant R, et al. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res. 1997 Jun;386(3):209–218. [PubMed] [Google Scholar]
  • Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A, Boorman GA, Foley JF, Yoshida T, et al. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol. 1998 Dec;153(6):1775–1785. [PMC free article] [PubMed] [Google Scholar]
  • Guha Mazumder DN, Haque R, Ghosh N, De BK, Santra A, Chakraborty D, Smith AH. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int J Epidemiol. 1998 Oct;27(5):871–877. [PubMed] [Google Scholar]
  • Hartwig A, Asmuss M, Ehleben I, Herzer U, Kostelac D, Pelzer A, Schwerdtle T, Bürkle A. Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ Health Perspect. 2002 Oct;110 (Suppl 5):797–799. [PMC free article] [PubMed] [Google Scholar]
  • Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8103–8107. [PMC free article] [PubMed] [Google Scholar]
  • Hu Y, Su L, Snow ET. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat Res. 1998 Sep 11;408(3):203–218. [PubMed] [Google Scholar]
  • Huang C, Li J, Ding M, Wang L, Shi X, Castranova V, Vallyathan V, Ju G, Costa M. Arsenic-induced NFkappaB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem. 2001 Jun;222(1-2):29–34. [PubMed] [Google Scholar]
  • Huff J, Chan P, Waalkes M. Arsenic carcinogenicity testing. Environ Health Perspect. 1998 Apr;106(4):A170–A170. [PMC free article] [PubMed] [Google Scholar]
  • Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. [PubMed] [Google Scholar]
  • Kaufmann WK. Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer Metastasis Rev. 1995 Mar;14(1):31–41. [PubMed] [Google Scholar]
  • Li JH, Rossman TG. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. Mol Toxicol. 1989 Winter;2(1):1–9. [PubMed] [Google Scholar]
  • Maier Andrew, Schumann Brenda L, Chang Xiaoqing, Talaska Glenn, Puga Alvaro. Arsenic co-exposure potentiates benzo[a]pyrene genotoxicity. Mutat Res. 2002 May 27;517(1-2):101–111. [PubMed] [Google Scholar]
  • Mure Kanae, Uddin Ahmed N, Lopez Laura C, Styblo Miroslav, Rossman Toby G. Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ Mol Mutagen. 2003;41(5):322–331. [PubMed] [Google Scholar]
  • Rossman TG. Enhancement of UV-mutagenesis by low concentrations of arsenite in E. coli. Mutat Res. 1981 May;91(3):207–211. [PubMed] [Google Scholar]
  • Rossman TG, Uddin AN, Burns FJ, Bosland MC. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64–71. [PubMed] [Google Scholar]
  • Schlatterer K, Schlatterer B, Krauter G, Hecker E, Chandra P. A novel polypeptide p10 expressed in tumor-promoter-treated murine epidermis and in untreated neonatal murine epidermis. Anticancer Res. 2000 Jan-Feb;20(1A):289–292. [PubMed] [Google Scholar]
  • Simeonova PP, Luster MI. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol. 2000;19(3):281–286. [PubMed] [Google Scholar]
  • Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol. 2001 May 1;172(3):225–232. [PubMed] [Google Scholar]
  • Viren J, Silvers A. Nonlinearity in the lung cancer dose-response for airborne arsenic: apparent confounding by year of hire in evaluating lung cancer risks from arsenic exposure in Tacoma smelter workers. Regul Toxicol Pharmacol. 1999 Oct;30(2 Pt 1):117–129. [PubMed] [Google Scholar]
  • Vogt BL, Rossman TG. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts -- a possible mechanism for arsenite's comutagenicity. Mutat Res. 2001 Jul 1;478(1-2):159–168. [PubMed] [Google Scholar]
  • Warner ML, Moore LE, Smith MT, Kalman DA, Fanning E, Smith AH. Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):583–590. [PubMed] [Google Scholar]
  • Yager JW, Wiencke JK. Enhancement of chromosomal damage by arsenic: implications for mechanism. Environ Health Perspect. 1993 Oct;101 (Suppl 3):79–82. [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

-